{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T18:40:57Z","timestamp":1762540857636,"version":"3.37.3"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Statutory fund of the Maj Institute of Pharmacology, Polish Academy of Sciences, Krak\u00f3w, Poland.","award":["Statutory fund of the Maj Institute of Pharmacology, Polish Academy of Sciences, Krak\u00f3w, Poland."],"award-info":[{"award-number":["Statutory fund of the Maj Institute of Pharmacology, Polish Academy of Sciences, Krak\u00f3w, Poland."]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Phencyclidine, an NMDA receptor antagonist, is frequently used to model behavioral and neurochemical changes correlated with schizophrenia in laboratory animals. The present study aimed to examine the effects of repeated administration of phencyclidine during early postnatal development on the contents of glutathione and sulfur-containing amino acids, as well as the activity of antioxidant enzymes in the brain of 12-day-old rats, and schizophrenia-like symptoms in adulthood.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Male Sprague-Dawley pups were administered phencyclidine (10\u00a0mg\/kg) or saline subcutaneously on the postnatal days p2, p6, p9 and p12. In 12-day-old pups, 4\u00a0h after the last dose of phencyclidine, the levels of glutathione, cysteine, methionine, and homocysteine, and the enzymatic activity of superoxide dismutase (SOD), glutathione peroxidase (GPx), and glutathione reductase (GR) were measured in the frontal cortex, hippocampus, and striatum. In 70-72-day-old rats, schizophrenia-like symptoms were assessed using behavioral tests.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Biochemical data showed that perinatal phencyclidine treatment significantly reduced glutathione and cysteine levels in all brain structures studied, methionine was diminished in the striatum, and homocysteine in both the frontal cortex and striatum. GR activity was increased in the frontal cortex while SODactivity was decreased in the hippocampus. Behaviorally, perinatal phencyclidine induced long-term deficits in social and cognitive function and a decrease in locomotor activity assessed as the time of walking. Finally, perinatal treatment with phencyclidine resulted in a significant reduction in body weight gain over time.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our research provides further evidence for the usefulness of the phencyclidine-induced neurodevelopmental model of schizophrenia for studying the pathogenesis of schizophrenia.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s43440-024-00607-3","type":"journal-article","created":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T05:01:38Z","timestamp":1718946098000},"page":"863-877","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The effect of phencyclidine-mediated blockade of NMDA receptors in the early postnatal period on glutathione and sulfur amino acid levels in the rat brain as a potential causative factor of schizophrenia-like behavior in adulthood"],"prefix":"10.1007","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9970-8548","authenticated-orcid":false,"given":"El\u017cbieta","family":"Lorenc-Koci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"G\u00f3rny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gra\u017cyna","family":"Chwatko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kinga","family":"Kami\u0144ska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma\u0142gorzata","family":"Iciek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zofia","family":"Rog\u00f3\u017c","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,21]]},"reference":[{"key":"607_CR1","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(09)60995-8","volume":"374","author":"J van Os","year":"2009","unstructured":"van Os J, Kapur S, Schizophrenia. Lancet. 2009;374:635\u201345.","journal-title":"Lancet"},{"key":"607_CR2","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nature09563","volume":"468","author":"J van Os","year":"2010","unstructured":"van Os J, Kenis G, Rutten BPF. The environment and schizophrenia. Nature. 2010;468:203\u201312.","journal-title":"Nature"},{"key":"607_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1001\/archpsyc.64.1.19","volume":"64","author":"J Perala","year":"2007","unstructured":"Perala J, Suvisaari J, Saarni SI, Kuoppasalmi K, Isometsa E, Pirkola S, et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry. 2007;64:19\u201328.","journal-title":"Arch Gen Psychiatry"},{"key":"607_CR4","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.biopsych.2017.08.017","volume":"83","author":"R Hilker","year":"2018","unstructured":"Hilker R, Helenius D, Fagerlund B, Skytthe A, Christensen K, Werge TM, et al. Heritability of schizophrenia and schizophrenia spectrum based on the nationwide Danish twin Register. Biol Psychiatry. 2018;83:492\u201398.","journal-title":"Biol Psychiatry"},{"key":"607_CR5","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1093\/schbul\/sbn117","volume":"34","author":"J van Os","year":"2008","unstructured":"van Os J, Rutten BP, Poulton R. Gene-environment interactions in schizophrenia: review of epidemiological findings and future directions. Schizophr Bull. 2008;34:1066\u201382.","journal-title":"Schizophr Bull"},{"key":"607_CR6","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.ijdevneu.2010.10.003","volume":"29","author":"JL Rapoport","year":"2011","unstructured":"Rapoport JL, Gogtay N. Childhood onset schizophrenia: support for a progressive neurodevelopmental disorder. Int J Dev Neurosci. 2011;29:251\u201358.","journal-title":"Int J Dev Neurosci"},{"key":"607_CR7","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.neubiorev.2010.10.008","volume":"35","author":"BK Bitanihirwe","year":"2011","unstructured":"Bitanihirwe BK, Woo TU. Oxidative stress in schizophrenia: an integrated approach. Neurosci Biobehav Rev. 2011;35:878\u201393.","journal-title":"Neurosci Biobehav Rev"},{"key":"607_CR8","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.conb.2009.05.001","volume":"19","author":"KQ Do","year":"2009","unstructured":"Do KQ, Cabungcal JH, Frank A, Steullet P, Cuenod M. Redox dysregulation, neurodevelopment, and schizophrenia. Curr Opin Neurobiol. 2009;19:220\u201330.","journal-title":"Curr Opin Neurobiol"},{"key":"607_CR9","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1089\/ars.2010.3603","volume":"15","author":"JK Yao","year":"2011","unstructured":"Yao JK, Keshavan MS. Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view. Antioxid Redox Signal. 2011;15:2011\u2013035.","journal-title":"Antioxid Redox Signal"},{"key":"607_CR10","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/S0166-2236(02)02245-2","volume":"25","author":"SA Lipton","year":"2002","unstructured":"Lipton SA, Cho Y-B, Takahashi H, Zhang D, Li W, Godzik A, Bankston LA. Cysteine regulation of protein function as exemplified by NMDA\u2013receptor modulation. Trends Neurosci. 2002;25:474\u201380.","journal-title":"Trends Neurosci"},{"key":"607_CR11","first-page":"269","volume-title":"Studies on Psychiatric disorders. Oxidative stress in Applied Basic Research and Clinical Practice","author":"E Lorenc-Koci","year":"2015","unstructured":"Lorenc-Koci E. Dysregulation of glutathione synthesis in psychiatric disorders. In: Dietrich-Muszalska A, Chauhan V, Grignon S, editors. Studies on Psychiatric disorders. Oxidative stress in Applied Basic Research and Clinical Practice. 1st ed. New York, NY, USA; Heidelberg, Germany; Dordrecht, The Netherlands; London, UK: Springer; 2015. pp. 269\u201399.","edition":"1"},{"key":"607_CR12","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1523\/JNEUROSCI.3857-09.2010","volume":"30","author":"P Steullet","year":"2010","unstructured":"Steullet P, Cabungcal JH, Kulak A, Kraftsik R, Chen Y, Dalton TP, et al. Redox dysregulation affects the ventral but not dorsal hippocampus: impairment of parvalbumin neurons, gamma oscillations, and related behaviors. J Neurosci. 2010;30:2547\u201358.","journal-title":"J Neurosci"},{"key":"607_CR13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.schres.2014.06.021","volume":"176","author":"P Steullet","year":"2016","unstructured":"Steullet P, Cabungcal JH, Monin A, Dwir D, O\u2019Donnell P, Cuenod M, Do KQ. Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: a central hub in schizophrenia pathophysiology? Schizophr Res. 2016;176:41\u201351.","journal-title":"Schizophr Res"},{"key":"607_CR14","doi-asserted-by":"publisher","first-page":"4253","DOI":"10.3390\/molecules24234253","volume":"24","author":"M G\u00f3rny","year":"2019","unstructured":"G\u00f3rny M, Wnuk A, Kami\u0144ska A, Kami\u0144ska K, Chwatko G, Bilska-Wilkosz A, et al. Glutathione deficiency and alterations in the sulfur amino acid homeostasis during early postnatal development as potential triggering factors for schizophrenia-like behavior in adult rats. Molecules. 2019;24:4253.","journal-title":"Molecules"},{"key":"607_CR15","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.biopsych.2020.03.016","volume":"88","author":"DO Perkins","year":"2020","unstructured":"Perkins DO, Jeffries CD, Do KQ. Potential roles of redox dysregulation in the development of schizophrenia. Biol Psychiatry. 2020;88:326\u201336.","journal-title":"Biol Psychiatry"},{"key":"607_CR16","doi-asserted-by":"publisher","first-page":"6761","DOI":"10.1038\/ncomms7761","volume":"6","author":"PS Baxter","year":"2015","unstructured":"Baxter PS, Bell KFS, Hasel P, Kaindl AM, Fricker M, Thomson D, et al. Synaptic NMDA receptor activity is coupled to the transcriptional control of the glutathione system. Nat Commun. 2015;6:6761.","journal-title":"Nat Commun"},{"key":"607_CR17","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1089\/ars.2006.8.1865","volume":"8","author":"DP Jones","year":"2006","unstructured":"Jones DP. Redefining oxidative stress. Antioxid Redox Signal. 2006;8:865\u201379.","journal-title":"Antioxid Redox Signal"},{"key":"607_CR18","doi-asserted-by":"publisher","first-page":"C849","DOI":"10.1152\/ajpcell.00283.2008","volume":"295","author":"DP Jones","year":"2008","unstructured":"Jones DP. Radical-free biology of oxidative stress. Am J Physiol Cell Physiol. 2008;295:C849\u201368.","journal-title":"Am J Physiol Cell Physiol"},{"key":"607_CR19","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1515\/BC.2003.059","volume":"384","author":"R Dringen","year":"2003","unstructured":"Dringen R, Hirrlinger J. Glutathione pathways in the brain. Biol Chem. 2003;384:505\u201316.","journal-title":"Biol Chem"},{"key":"607_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1042\/BJ20111943","volume":"443","author":"S Fernandez-Fernandez","year":"2012","unstructured":"Fernandez-Fernandez S, Almeida A, Bolanos JP. Antioxidant and bioenergetic coupling between neurons and astrocytes. Biochem J. 2012;443:3\u201311.","journal-title":"Biochem J"},{"key":"607_CR21","doi-asserted-by":"publisher","first-page":"3721","DOI":"10.1046\/j.1460-9568.2000.00229.x","volume":"12","author":"KQ Do","year":"2000","unstructured":"Do KQ, Trabesinger AH, Kirsten-Kr\u00fcger M, Lauer CJ, Dydak U, Hell D, et al. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci. 2000;12:3721\u201328.","journal-title":"Eur J Neurosci"},{"key":"607_CR22","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1089\/ars.2010.3453","volume":"15","author":"D Matsuzawa","year":"2011","unstructured":"Matsuzawa D, Hashimoto K. Magnetic resonance spectroscopy study of the antioxidant defense system in schizophrenia. Antioxid Redox Signal. 2011;15:2057\u201365.","journal-title":"Antioxid Redox Signal"},{"key":"607_CR23","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1155\/2006\/248387","volume":"22","author":"JK Yao","year":"2006","unstructured":"Yao JK, Leonard S, Reddy R. Altered glutathione redox state in schizophrenia. Dis Markers. 2006;22:83\u201393.","journal-title":"Dis Markers"},{"key":"607_CR24","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1017\/S1461145710000805","volume":"14","author":"JW Gawryluk","year":"2011","unstructured":"Gawryluk JW, Wang JF, Andreazza AC, Shao L, Young LT. Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. Int J Neuropsychopharmacol. 2011;14:123\u201330.","journal-title":"Int J Neuropsychopharmacol"},{"key":"607_CR25","doi-asserted-by":"publisher","first-page":"e1944","DOI":"10.1371\/journal.pone.0001944","volume":"3","author":"D Matsuzawa","year":"2008","unstructured":"Matsuzawa D, Obata T, Shirayama Y, Nonaka H, Kanazawa Y, Yoshitome E, et al. Negative correlation between brain glutathione level and negative symptoms in schizophrenia: a 3T 1H-MRS study. PLoS ONE. 2008;3:e1944.","journal-title":"PLoS ONE"},{"key":"607_CR26","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1086\/507566","volume":"79","author":"M Tosic","year":"2006","unstructured":"Tosic M, Ott J, Barral S, Bovet P, Deppen P, Gheorghita F, et al. Schizophrenia and oxidative stress: glutamate cysteine ligase modifier as a susceptibility gene. Am J Hum Genet. 2006;79:586\u201392.","journal-title":"Am J Hum Genet"},{"key":"607_CR27","doi-asserted-by":"publisher","first-page":"16621","DOI":"10.1073\/pnas.0706778104","volume":"104","author":"R Gysin","year":"2007","unstructured":"Gysin R, Kraftsik R, Sandell J, Bovet P, Chappuis C, Conus P, et al. Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence. Proc Natl Acad Sci USA. 2007;104:16621\u201326.","journal-title":"Proc Natl Acad Sci USA"},{"key":"607_CR28","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1089\/ars.2010.3463","volume":"15","author":"R Gysin","year":"2011","unstructured":"Gysin R, Kraftsik R, Boulat O, Bovet P, Conus P, Comte-Krieger E, et al. Genetic dysregulation of glutathione synthesis predicts alteration of plasma thiol redox status in schizophrenia. Antioxid Redox Signal. 2011;15:2003\u201310.","journal-title":"Antioxid Redox Signal"},{"key":"607_CR29","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1523\/JNEUROSCI.19-02-00562.1999","volume":"19","author":"R Dringen","year":"1999","unstructured":"Dringen R, Pfeier B, Hamprecht B. Synthesis of the antioxidant glutathione in neurons: supply by astrocytes of CysGly as precursor for neuronal glutathione. J Neurosci. 1999;19:562\u201369.","journal-title":"J Neurosci"},{"key":"607_CR30","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1016\/j.bbagen.2012.09.008","volume":"1830","author":"SC Lu","year":"2013","unstructured":"Lu SC. Glutathione synthesis. Biochim Biophys Acta. 2013;1830:3143\u201353.","journal-title":"Biochim Biophys Acta"},{"key":"607_CR31","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1002\/1098-2396(20001215)38:4<369::AID-SYN1>3.0.CO;2-Q","volume":"38","author":"W Almaguer-Melian","year":"2000","unstructured":"Almaguer-Melian W, Cruz-Aguado R, Bergado JA. Synaptic plasticity is impaired in rats with a low glutathione content. Synapse. 2000;38:369\u201374.","journal-title":"Synapse"},{"key":"607_CR32","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S0361-9230(01)00484-1","volume":"55","author":"R Cruz-Aguado","year":"2001","unstructured":"Cruz-Aguado R, Almaguer-Melian W, D\u00edaz CM, Lorigados L, Bergado J. Behavioral and biochemical effects of glutathione depletion in the rat brain. Brain Res Bull. 2001;55:327\u201333.","journal-title":"Brain Res Bull"},{"key":"607_CR33","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.nbd.2003.09.005","volume":"15","author":"V Castagn\u00e9","year":"2004","unstructured":"Castagn\u00e9 V, Rougemont M, Cuenod M, Do KQ. Low brain glutathione and ascorbic acid associated with dopamine uptake inhibition during rat\u2019s development induce long-term cognitive deficit: relevance to schizophrenia. Neurobiol Dis. 2004;15:93\u2013105.","journal-title":"Neurobiol Dis"},{"key":"607_CR34","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.nbd.2007.03.001","volume":"26","author":"JH Cabungcal","year":"2007","unstructured":"Cabungcal JH, Preissmann D, Delseth C, Cu\u00e9nod M, Do KQ, Schenk F. Transitory glutathione deficit during brain development induces cognitive impairment in juvenile and adult rats: relevance to schizophrenia. Neurobiol Dis. 2007;26:634\u201345.","journal-title":"Neurobiol Dis"},{"key":"607_CR35","doi-asserted-by":"publisher","first-page":"6171","DOI":"10.3390\/ijms22126171","volume":"22","author":"MA Lech","year":"2021","unstructured":"Lech MA, Le\u015bkiewicz M, Kami\u0144ska K, Rog\u00f3\u017c Z, Lorenc-Koci E. Glutathione deficiency during early postnatal development causes schizophrenia-like symptoms and a reduction in BDNF levels in the cortex and hippocampus of adult Sprague-Dawley rats. Int J Mol Sci. 2021;22:6171.","journal-title":"Int J Mol Sci"},{"key":"607_CR36","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.mam.2008.08.009","volume":"30","author":"CC Franklin","year":"2009","unstructured":"Franklin CC, Backos DS, Mohar I, White CC, Forman HJ, Kavanagh TJ. Structure, function, and post-translational regulation of the catalytic and modifier subunits of glutamate cysteine ligase. Mol Aspects Med. 2009;30:86\u201398.","journal-title":"Mol Aspects Med"},{"key":"607_CR37","doi-asserted-by":"publisher","first-page":"49446","DOI":"10.1074\/jbc.M209372200","volume":"277","author":"Y Yang","year":"2002","unstructured":"Yang Y, Dieter MZ, Chen Y, Shertzer HG, Nebert DW, Dalton TP. Initial characterization of the Gclm(-\/-) glutamate-cysteine ligase modifier subunit knockout mouse. Novel model system for a severely compromised oxidative stress response. J Biol Chem. 2002;277:49446\u201352.","journal-title":"J Biol Chem"},{"key":"607_CR38","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1006\/bbrc.2000.3930","volume":"279","author":"TP Dalton","year":"2000","unstructured":"Dalton TP, Dieter MZ, Yang Y, Shertzer HG, Neber DW. Knockout of the mouse glutamate cysteine ligase catalytic subunit (gclc) gene: embryonic lethal when homozygous, and proposed model for moderate glutathione deficiency when heterozygous. Biochem Biophys Res Commun. 2000;279:324\u20139.","journal-title":"Biochem Biophys Res Commun"},{"key":"607_CR39","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/j.freeradbiomed.2004.06.040","volume":"37","author":"TP Dalton","year":"2004","unstructured":"Dalton TP, Chen Y, Schneider SN, Nebert DW, Shertzer HG. Genetically altered mice to evaluate glutathione homeostasis in health and disease. Free Radic Biol Med. 2004;37:1511\u201326.","journal-title":"Free Radic Biol Med"},{"key":"607_CR40","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/S0021-9258(19)41830-9","volume":"250","author":"PG Richman","year":"1975","unstructured":"Richman PG, Meister A. Regulation of gamma-glutamyl-cysteine synthetase by nonallosteric feedback inhibition by glutathione. J Biol Chem. 1975;250:1422\u20136.","journal-title":"J Biol Chem"},{"key":"607_CR41","doi-asserted-by":"publisher","first-page":"9345","DOI":"10.1016\/S0021-9258(17)42703-7","volume":"259","author":"GF Seelig","year":"1984","unstructured":"Seelig GF, Simondsen RP, Meister A. Reversible dissociation of gamma-glutamylcysteine synthetase into two subunits. J Biol Chem. 1984;259:9345\u20137.","journal-title":"J Biol Chem"},{"key":"607_CR42","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.neuropharm.2009.12.009","volume":"58","author":"NV Radonji\u0107","year":"2010","unstructured":"Radonji\u0107 NV, Knezevi\u0107 ID, Vilimanovich U, Kravi\u0107-Stevovi\u0107 T, Marina LV, Nikoli\u0107 T, et al. Decreased glutathione levels and altered antioxidant defense in an animal model of schizophrenia: long-term effects of perinatal phencyclidine administration. Neuropharmacology. 2010;58:739\u201345.","journal-title":"Neuropharmacology"},{"key":"607_CR43","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0306-4522(01)00384-0","volume":"107","author":"C Wang","year":"2001","unstructured":"Wang C, McInnis J, Ross-Sanchez M, Shinnick-Gallagher P, Wiley JL, Johnson KM. Long-term behavioral and neurodegenerative effects of perinatal phencyclidine administration: implications for schizophrenia. Neuroscience. 2001;107:535\u201350.","journal-title":"Neuroscience"},{"key":"607_CR44","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1124\/jpet.102.041798","volume":"304","author":"C Wang","year":"2003","unstructured":"Wang C, McInnis J, West JB, Bao J, Anastasio N, Guidry JA, et al. Blockade of phencyclidine-induced cortical apoptosis and deficits in prepulse inhibition by M40403, a superoxide dismutase mimetic. J Pharmacol Exp Ther. 2003;304:266\u201371.","journal-title":"J Pharmacol Exp Ther"},{"key":"607_CR45","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1111\/j.1471-4159.2006.04106.x","volume":"99","author":"M Takahashi","year":"2006","unstructured":"Takahashi M, Kakita A, Futamura T, Watanabe Y, Mizuno M, Sakimura K, et al. Sustained brain-derived neurotrophic factor up-regulation and sensorimotor gating abnormality induced by postnatal exposure to phencyclidine: comparison with adult treatment. J Neurochem. 2006;99:770\u201380.","journal-title":"J Neurochem"},{"key":"607_CR46","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/7854_2015_403","volume":"29","author":"B Grayson","year":"2016","unstructured":"Grayson B, Barnes SA, Markou A, Piercy C, Podda G, Neill JC. Postnatal phencyclidine (PCP) as a neurodevelopmental animal model of schizophrenia pathophysiology and symptomatology: a review. Curr Top Behav Neurosci. 2016;29:403\u201328.","journal-title":"Curr Top Behav Neurosci"},{"issue":"6","key":"607_CR47","doi-asserted-by":"publisher","first-page":"538","DOI":"10.3390\/antiox9060538","volume":"9","author":"M G\u00f3rny","year":"2020","unstructured":"G\u00f3rny M, Bilska-Wilkosz A, Iciek M, Hereta M, Kami\u0144ska K, Kami\u0144ska A, et al. Alterations in the antioxidant enzyme activities in the neurodevelopmental rat model of schizophrenia induced by glutathione deficiency during early postnatal life. Antioxidants. 2020;9(6):538.","journal-title":"Antioxidants"},{"issue":"3","key":"607_CR48","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.physbeh.2007.10.003","volume":"93","author":"NV Radonji\u0107","year":"2008","unstructured":"Radonji\u0107 NV, Petronijevi\u0107 ND, Vuckovi\u0107 SM, Prostran MS, Nesi\u0107 ZI, Todorovi\u0107 VR, Paunovi\u0107 VR. Baseline temperature in an animal model of schizophrenia: long-term effects of perinatal phencyclidine administration. Physiol Behav. 2008;93(3):437\u201343.","journal-title":"Physiol Behav"},{"key":"607_CR49","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1081\/JLC-100103450","volume":"24","author":"E Bald","year":"2001","unstructured":"Bald E, G\u0142owacki R. 2-Chloro-1-methylquinolinium tetrafluoroborate as an effective and thiol specific uv-tagging reagent for liquid chromatography. J Liq Chrom Rel Technol. 2001;24:1323\u201339.","journal-title":"J Liq Chrom Rel Technol"},{"key":"607_CR50","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.chroma.2003.11.030","volume":"1032","author":"E Bald","year":"2004","unstructured":"Bald E, Chwatko G, G\u0142owacki R, Ku\u015bmierek K. Analysis of plasma thiols by high-performance liquid chromatography with ultraviolet detection. J Chromatogr. 2004;1032:109\u201315.","journal-title":"J Chromatogr"},{"key":"607_CR51","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1002\/jssc.201800381","volume":"41","author":"A Kami\u0144ska","year":"2018","unstructured":"Kami\u0144ska A, Olejarz P, Borowczyk K, G\u0142owacki R, Chwatko G. Simultaneous determination of total homocysteine, cysteine, glutathione and N-acetylcysteine in brain homogenates by HPLC. J Sep Sci. 2018;41:3241\u20139.","journal-title":"J Sep Sci"},{"key":"607_CR52","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.talanta.2016.09.039","volume":"161","author":"K Borowczyk","year":"2016","unstructured":"Borowczyk K, Chwatko G, Kubalczyk P, Jakubowski H, Kubalska J, G\u0142owacki R. Simultaneous determination of methionine and homocysteine by on-column derivatization with o-phtaldialdehyde. Talanta. 2016;161:917\u201324.","journal-title":"Talanta"},{"key":"607_CR53","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","volume":"193","author":"OH Lowry","year":"1951","unstructured":"Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265\u201375.","journal-title":"J Biol Chem"},{"key":"607_CR54","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1146\/annurev.bi.52.070183.003431","volume":"52","author":"A Meister","year":"1983","unstructured":"Meister A, Anderson ME, Glutathione. Annu Rev Biochem. 1983;52:711\u201360.","journal-title":"Annu Rev Biochem"},{"key":"607_CR55","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1515\/CCLM.2007.341","volume":"45","author":"JD Finkelstein","year":"2007","unstructured":"Finkelstein JD. Metabolic regulatory properties of S-adenosylmethionine and S-adenosylhomocysteine. Clin Chem Lab Med. 2007;45:1694\u20139.","journal-title":"Clin Chem Lab Med"},{"key":"607_CR56","doi-asserted-by":"publisher","first-page":"35785","DOI":"10.1074\/jbc.M602799200","volume":"28","author":"V Vitvitsky","year":"2006","unstructured":"Vitvitsky V, Thomas M, Ghorpade A, Gendelman HE, Banerjee R. A functional transsulfuration pathway in the brain links to glutathione homeostasis. J Biol Chem. 2006;28:35785\u201393.","journal-title":"J Biol Chem"},{"key":"607_CR57","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1523\/JNEUROSCI.16-03-01066.1996","volume":"16","author":"K Abe","year":"1996","unstructured":"Abe K, Kimura H. The possible role of hydrogen sulfide as an endogenous neuromodulator. J Neurosci. 1996;16:1066\u201371.","journal-title":"J Neurosci"},{"key":"607_CR58","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.tibs.2015.08.007","volume":"40","author":"BD Paul","year":"2015","unstructured":"Paul BD, Snyder SH. H2S: a novel gasotransmitter that signals by sulfhydration. Trends Biochem Sci. 2015;40:687\u2013700.","journal-title":"Trends Biochem Sci"},{"issue":"5","key":"607_CR59","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.neuint.2013.09.003","volume":"63","author":"H Kimura","year":"2013","unstructured":"Kimura H. Physiological role of hydrogen sulfide and polysulfide in the central nervous system. Neurochem Int. 2013;63(5):492\u20137.","journal-title":"Neurochem Int"},{"key":"607_CR60","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1007\/s00213-018-4923-7","volume":"235","author":"JW Xiong","year":"2018","unstructured":"Xiong JW, Wei B, Li YK, Zhan JQ, Jiang SZ, Chen HB, et al. Decreased plasma levels of gasotransmitter hydrogen sulfide in patients with schizophrenia: correlation with psychopathology and cognition. Psychopharmacology. 2018;235:2267\u201374.","journal-title":"Psychopharmacology"},{"key":"607_CR61","doi-asserted-by":"publisher","first-page":"e10695","DOI":"10.15252\/emmm.201910695","volume":"11","author":"M Ide","year":"2019","unstructured":"Ide M, Ohnishi T, Toyoshima M, Balan S, Maekawa M, Shimamoto-Mitsuyama C, et al. Excess hydrogen sulfide and polysulfides production underlies a schizophrenia pathophysiology. EMBO Mol Med. 2019;11:e10695.","journal-title":"EMBO Mol Med"},{"key":"607_CR62","doi-asserted-by":"publisher","first-page":"896","DOI":"10.3390\/biom11060896","volume":"11","author":"H Kimura","year":"2021","unstructured":"Kimura H. Hydrogen sulfide (H(2)S) and polysulfide (H(2)S(n)) signaling: the first 25 years. Biomolecules. 2021;11:896.","journal-title":"Biomolecules"},{"key":"607_CR63","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.ebiom.2019.05.062","volume":"45","author":"T Ohnishi","year":"2019","unstructured":"Ohnishi T, Balan S, Toyoshima M, Maekawa M, Ohba H, Watanabe A, et al. Investigation of betaine as a novel psychotherapeutic for schizophrenia. EBioMedicine. 2019;45:432\u201346.","journal-title":"EBioMedicine"},{"key":"607_CR64","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1096\/fj.12-226415","volume":"27","author":"Y Kimura","year":"2013","unstructured":"Kimura Y, Mikami Y, Osumi K, Tsugane M, Oka J, Kimura H. Polysulfides are possible H2S-derived signaling molecules in rat brain. FASEB J. 2013;27:2451\u201357.","journal-title":"FASEB J"},{"key":"607_CR65","doi-asserted-by":"crossref","unstructured":"Kimura H. (2019) Signaling by hydrogen sulfide (H2S) and polysulfides (H2Sn) in the central nervous system. Neurochem Int. 2019;126, 118\u201325.","DOI":"10.1016\/j.neuint.2019.01.027"},{"key":"607_CR66","doi-asserted-by":"publisher","first-page":"5773","DOI":"10.1111\/febs.16944","volume":"290","author":"M G\u00f3rny","year":"2023","unstructured":"G\u00f3rny M, Bilska-Wilkosz A, Iciek M, Rog\u00f3\u017c Z, Lorenc-Koci E. Treatment with aripiprazole and N-acetylcysteine affects anaerobic cysteine metabolism in the hippocampus and reverses schizophrenia-like behavior in the neurodevelopmental rat model of schizophrenia. FEBS J. 2023;290:5773\u201393.","journal-title":"FEBS J"},{"issue":"3","key":"607_CR67","doi-asserted-by":"publisher","first-page":"324","DOI":"10.2174\/0929867324666170609075434","volume":"25","author":"MB Colovic","year":"2018","unstructured":"Colovic MB, Vasic VM, Djuric DM, Krstic DZ. Sulphur-containing amino acids: protective role against free radicals and heavy metals. Curr Med Chem. 2018;25(3):324\u201335.","journal-title":"Curr Med Chem"},{"key":"607_CR68","doi-asserted-by":"publisher","first-page":"9508","DOI":"10.1016\/S0021-9258(17)42728-1","volume":"259","author":"JD Finkelstein","year":"1984","unstructured":"Finkelstein JD, Martin JJ. Methionine metabolism in mammals. Distribution of homocysteine between competing pathways. J Biol Chem. 1984;259:9508\u201313.","journal-title":"J Biol Chem"},{"key":"607_CR69","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/S0021-9258(17)35979-3","volume":"261","author":"JD Finkelstein","year":"1986","unstructured":"Finkelstein JD, Martin JJ. Methionine metabolism in mammals. Adaptation to methionine excess. J Biol Chem. 1986;261:1582\u201387.","journal-title":"J Biol Chem"},{"key":"607_CR70","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.ymgme.2014.10.006","volume":"113","author":"PR Mandaviya","year":"2014","unstructured":"Mandaviya PR, Stolk L, Heil SG. Homocysteine and DNA methylation: a review of animal and human literature. Mol Genet Metab. 2014;113:243\u201352.","journal-title":"Mol Genet Metab"},{"key":"607_CR71","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/978-3-319-53889-1_12","volume":"978","author":"K Pries","year":"2017","unstructured":"Pries K, G\u00fcl\u00f6ks\u00fcz S, Kenis G. DNA methylation in schizophrenia. Adv Exp Med Biol. 2017;978:211\u201336.","journal-title":"Adv Exp Med Biol"},{"key":"607_CR72","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0893-133X(01)00230-5","volume":"25","author":"A Balla","year":"2001","unstructured":"Balla A, Koneru R, Smiley J, Sershen H, Javitt DC. Continuous phencyclidine treatment induces schizophrenia-like hyperreactivity of striatal dopamine release. Neuropsychopharmacology. 2001;25:157\u201364.","journal-title":"Neuropsychopharmacology"},{"key":"607_CR73","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.neuropharm.2017.11.045","volume":"142","author":"D Cadinu","year":"2018","unstructured":"Cadinu D, Grayson B, Podda G, Harte MK, Doostdar N, Neill JC. NMDA receptor antagonist rodent models for cognition in schizophrenia and identification of novel drug treatments, an update. Neuropharmacology. 2018;142:41\u201362.","journal-title":"Neuropharmacology"},{"key":"607_CR74","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3389\/fnmol.2019.00185","volume":"12","author":"G Lee","year":"2019","unstructured":"Lee G, Zhou Y. NMDAR hypofunction animal models of schizophrenia. Front Mol Neurosci. 2019;12:185.","journal-title":"Front Mol Neurosci"},{"issue":"2\u20134","key":"607_CR75","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.neuint.2007.06.019","volume":"51","author":"A Mouri","year":"2007","unstructured":"Mouri A, Noda Y, Enomoto T, Nabeshima T. Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment. Neurochem Int. 2007;51(2\u20134):173\u201384.","journal-title":"Neurochem Int"},{"issue":"3","key":"607_CR76","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.pharmthera.2010.07.004","volume":"128","author":"JC Neill","year":"2010","unstructured":"Neill JC, Barnes S, Cook S, Grayson B, Idris NF, McLean SL, et al. Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacol Ther. 2010;128(3):419\u201332.","journal-title":"Pharmacol Ther"},{"issue":"5","key":"607_CR77","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.euroneuro.2013.09.011","volume":"24","author":"JC Neill","year":"2014","unstructured":"Neill JC, Harte MK, Haddad PM, Lydall ES, Dwyer DM. Acute and chronic effects of NMDA receptor antagonists in rodents, relevance to negative symptoms of schizophrenia: a translational link to humans. Eur Neuropsychopharmacol. 2014;24(5):822\u201335.","journal-title":"Eur Neuropsychopharmacol"},{"key":"607_CR78","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/0024-3205(94)00482-8","volume":"56","author":"K Kitaichi","year":"1995","unstructured":"Kitaichi K, Yamada K, Yoneda Y, Ogita K, Hasegawa T, Furukawa H, Nabeshima T. Risperidone prevents the development of supersensitivity, but not tolerance to phencyclidine in rats treated with subacute phencyclidine. Life Sci. 1995;56:531\u201343.","journal-title":"Life Sci"},{"issue":"1","key":"607_CR79","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/sj.npp.1300019","volume":"28","author":"A Balla","year":"2003","unstructured":"Balla A, Sershen H, Serra M, Koneru R, Javitt DC. Subchronic continuous phencyclidine administration potentiates amphetamine-induced frontal cortex dopamine release. Neuropsychopharmacology. 2003;28(1):34\u201344.","journal-title":"Neuropsychopharmacology"},{"key":"607_CR80","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0893-133X(98)00004-9","volume":"19","author":"JD Jentsch","year":"1998","unstructured":"Jentsch JD, Taylor JR, Roth RH. Subchronic phencyclidine administration increases mesolimbic dopaminergic system responsivity and augments stress- and psychostimulant-induced hyperlocomotion. Neuropsychopharmacology. 1998;19:105\u201313.","journal-title":"Neuropsychopharmacology"},{"key":"607_CR81","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/(SICI)1098-2396(19990301)31:3<229::AID-SYN8>3.0.CO;2-3","volume":"31","author":"T Hanania","year":"1999","unstructured":"Hanania T, Hillman GR, Johnson KM. Augmentation of locomotor activity by chronic phencyclidine is associated with an increase in striatal NMDA receptor function and an upregulation of the NR1 receptor subunit. Synapse. 1999;31:229\u201339.","journal-title":"Synapse"},{"key":"607_CR82","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1002\/(SICI)1097-4547(19980615)52:6<709::AID-JNR10>3.0.CO;2-U","volume":"52","author":"KM Johnson","year":"1998","unstructured":"Johnson KM, Phillips M, Wang C, Kevetter GA. Chronic phencyclidine induces behavioral sensitization and apoptotic cell death in the olfactory and piriform cortex. J Neurosci Res. 1998;52:709\u201322.","journal-title":"J Neurosci Res"},{"key":"607_CR83","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/0091-3057(94)90165-1","volume":"47","author":"X Xu","year":"1994","unstructured":"Xu X, Domino EF. Phencyclidine-induced behavioral sensitization. Pharmacol Biochem Behav. 1994;47:603\u20138.","journal-title":"Pharmacol Biochem Behav"},{"key":"607_CR84","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1176\/ajp.148.10.1301","volume":"148","author":"DC Javitt","year":"1991","unstructured":"Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991;148:1301\u20138.","journal-title":"Am J Psychiatry"},{"key":"607_CR85","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/0166-4328(95)00162-X","volume":"74","author":"RE Steinpreis","year":"1996","unstructured":"Steinpreis RE. The behavioral and neurochemical effects of phencyclidine in humans and animals: some implications for modeling psychosis. Behav Brain Res. 1996;74:45\u201355.","journal-title":"Behav Brain Res"},{"key":"607_CR86","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1002\/1097-4679(199101)47:1<159::AID-JCLP2270470125>3.0.CO;2-O","volume":"47","author":"J Cosgrove","year":"1991","unstructured":"Cosgrove J, Newell TG. Recovery of neuropsychological functions during reduction in use of phencyclidine. J Clin Psychol. 1991;47:159\u201369.","journal-title":"J Clin Psychol"},{"issue":"2","key":"607_CR87","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.freeradbiomed.2003.10.028","volume":"36","author":"C Dabrosin","year":"2004","unstructured":"Dabrosin C, Ollinger K. Variability of glutathione during the menstrual cycle-due to estrogen effects on hepatocytes? Free Radic Biol Med. 2004;36(2):145\u201351.","journal-title":"Free Radic Biol Med"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-024-00607-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-024-00607-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-024-00607-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T07:03:52Z","timestamp":1722495832000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-024-00607-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,21]]},"references-count":87,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["607"],"URL":"https:\/\/doi.org\/10.1007\/s43440-024-00607-3","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"type":"print","value":"1734-1140"},{"type":"electronic","value":"2299-5684"}],"subject":[],"published":{"date-parts":[[2024,6,21]]},"assertion":[{"value":"12 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}